255 related articles for article (PubMed ID: 31132977)
1. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
Kobak S
Curr Drug Saf; 2019; 14(3):225-229. PubMed ID: 31132977
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
Akagi Y; Awano N; Inomata M; Kuse N; Tone M; Yoshimura H; Jo T; Takada K; Kumasaka T; Izumo T
Intern Med; 2020 Apr; 59(8):1075-1080. PubMed ID: 32009093
[TBL] [Abstract][Full Text] [Related]
5. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
6. Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis.
Osa A; Uenami T; Naito Y; Hirata H; Koyama S; Takimoto T; Shiroyama T; Futami S; Nakatsubo S; Sawa N; Yano Y; Nagatomo I; Takeda Y; Mori M; Kida H; Kumanogoh A
Thorac Cancer; 2019 Nov; 10(11):2183-2187. PubMed ID: 31520515
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
8. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.
Spathas N; Economopoulou P; Cheila M; Kotsantis I; Fanouriakis A; Kassara D; Psyrri A
Front Oncol; 2018; 8():409. PubMed ID: 30319973
[No Abstract] [Full Text] [Related]
10. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
Bulat V; Likic R; Bradic L; Speeckaert R; Azdajic MD
Br J Clin Pharmacol; 2021 Jun; 87(6):2614-2618. PubMed ID: 33217043
[TBL] [Abstract][Full Text] [Related]
11. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
[No Abstract] [Full Text] [Related]
12. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
13. A case of severe Pembrolizumab-induced neutropenia.
Barbacki A; Maliha PG; Hudson M; Small D
Anticancer Drugs; 2018 Sep; 29(8):817-819. PubMed ID: 29889673
[TBL] [Abstract][Full Text] [Related]
14. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
[No Abstract] [Full Text] [Related]
16. Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis.
Imai M; Kosaka Y; Tachi M; Mori K; Maruno H
Clin Nucl Med; 2020 Dec; 45(12):999-1000. PubMed ID: 33086269
[TBL] [Abstract][Full Text] [Related]
17. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
19. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]